A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2011
12/01/2011	WO2011114239A3 Fat-binding compositions
12/01/2011	WO2011097336A3 Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor
12/01/2011	WO2011081488A3 Composition for treatment of obesity using wheat bran extract or active ingredient isolated therefrom
12/01/2011	WO2010083409A9 Companion animal compositions including pyruvic acid and salts thereof and methods of use thereof
12/01/2011	US20110295151 Enteroendocrine Manipulation for Metabolic Effect
12/01/2011	US20110294902 Pharmaceutical compositions providing enhanced drug concentrations
12/01/2011	US20110294885 Controlled-release pregabalin compositions
12/01/2011	US20110294883 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
12/01/2011	US20110294875 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
12/01/2011	US20110294870 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
12/01/2011	US20110294868 Modulation of transthyretin expression
12/01/2011	US20110294861 Method of treatment of hereditary hemochromatosis
12/01/2011	US20110294858 Substituted 6-methylnicotinamides as mglur5 positive allosteric modulators
12/01/2011	US20110294856 Novel oxadiazole derivatives and their medical use
12/01/2011	US20110294854 SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
12/01/2011	US20110294852 Pharmaceutical Formulation Comprising Metformin and Repaglinide
12/01/2011	US20110294836 Aryl gpr119 agonists and uses thereof
12/01/2011	US20110294833 Methods for Healthy Aging
12/01/2011	US20110294832 Fused ring compound and use thereof
12/01/2011	US20110294826 Pyrrolo[2,3-d]pyrimidine compounds
12/01/2011	US20110294825 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/01/2011	US20110294824 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
12/01/2011	US20110294821 5-ht1a receptor subtype agonist
12/01/2011	US20110294815 Prostacyclin analogs
12/01/2011	US20110294813 Oxazolidinone derivative having inhibitory activity on 11beta-hydroxysteroid dehydrogenase type 1
12/01/2011	US20110294809 Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betahsd1
12/01/2011	US20110294808 Indazole Compounds As CCR1 Receptor Antagonists
12/01/2011	US20110294807 Compounds for the prevention and treatment of cardiovascular disease
12/01/2011	US20110294805 Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators and methods of use thereof
12/01/2011	US20110294800 Hypoglycemic dihydropyridones
12/01/2011	US20110294794 Treatment of proteinopathies using a farnesyl transferase inhibitor
12/01/2011	US20110294792 Purine derivatives as kinase inhibitors
12/01/2011	US20110294788 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators
12/01/2011	US20110294786 Substituted bicyclic pyrimidone derivatives
12/01/2011	US20110294781 Pyrazolo-pyrimidine compounds
12/01/2011	US20110294780 SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
12/01/2011	US20110294772 Use of cyclosquaramide compounds as anti-tumour agents
12/01/2011	US20110294770 Method for producing pharmaceutical drug particles of small particle size
12/01/2011	US20110294764 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3
12/01/2011	US20110294759 Once daily formulations of tetracyclines
12/01/2011	US20110294758 Novel activators of glucokinase
12/01/2011	US20110294746 Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
12/01/2011	US20110294735 Mechanism of neuromedin u action and uses thereof
12/01/2011	US20110294729 Novel Insulin Analogues
12/01/2011	US20110294727 Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
12/01/2011	US20110294720 Apratoxin therapeutic agents: mechanism and methods of treatment
12/01/2011	US20110294665 Bioactive agent, pharmaceutical product, cosmetic product, freshness keeping agent, and plant and animal growth promoting agent
12/01/2011	US20110294146 Identification of Actinobacillus actinomycetemcomitans Antigens for Use in the Diagnosis, Treatment, and Monitoring of Periodontal Diseases
12/01/2011	US20110293733 Self-assembling nanoparticle drug delivery system
12/01/2011	US20110293730 Polylactide nanoparticles
12/01/2011	US20110293725 Chimeric therapeutics, compositions, and methods for using same
12/01/2011	US20110293715 Pharmaceutical Formulation and Process for Its Preparation
12/01/2011	US20110293714 Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
12/01/2011	US20110293711 Utilization of Dialkylfumarates
12/01/2011	US20110293706 Nanoshells on polymers
12/01/2011	US20110293676 Oral Cephalotaxine Dosage Forms
12/01/2011	US20110293673 Oral film-form base and oral film-form preparation
12/01/2011	US20110293647 Immunogenic lhrh compositions and methods relating thereto
12/01/2011	US20110293644 Compositions and methods for treatment of celiac disease
12/01/2011	US20110293639 Ideotypically modulated pharmacoeffectors for selective cell treatment
12/01/2011	US20110293610 Antibodies that immunospecifically bind to b lymphocyte stimulator protein
12/01/2011	US20110293603 Amino acid sequences directed against multitarget scavenger receptors and polypeptides
12/01/2011	US20110293595 Prophylactic and therapeutic treatment of Alzheimer's Disease, neuro-degenerative diseases, protein aggregation diseases, Parkinson's Disease and amyloid diseases, using phytic acid and phytate
12/01/2011	US20110293589 Method of treating vitamin b12 deficiency
12/01/2011	US20110293587 Glucagon analogues
12/01/2011	US20110293586 Glucagon analogues
12/01/2011	US20110293585 Compositions and methods for treatment of lysosomal storage disorders
12/01/2011	US20110293569 Lactobacillus rhamnosus cncm i-4096 and weight control
12/01/2011	US20110293568 Lactobacillus helveticus cncm i-4095 and weight control
12/01/2011	US20110293562 Use of cardiotrophin-1 for the treatment of metabolic diseases
12/01/2011	US20110293556 Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia
12/01/2011	US20110293545 Dolichos Biflorus Extract For Use In Cosmetic Skin Treatment
12/01/2011	US20110293539 Film containing compositions
12/01/2011	US20110293516 Compositions and methods of use of targeting peptides against placenta and adipose tissues
12/01/2011	CA2836175A1 Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
12/01/2011	CA2806619A1 Anti-diabetic compositions and methods
12/01/2011	CA2800581A1 Antibodies to human gdf8
12/01/2011	CA2800176A1 Bicyclic heteroaryl kinase inhibitors and methods of use
12/01/2011	CA2799591A1 Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
11/2011
11/30/2011	EP2390254A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND
11/30/2011	EP2389945A1 Pharmaceutical composition comprising AVE0010 and insulin glargine
11/30/2011	EP2389943A1 Use of IL-174 antagonists for treating Th2-related diseases
11/30/2011	EP2389378A1 Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
11/30/2011	EP2389374A1 Substituted pyrazinone amides
11/30/2011	EP2389369A1 Pentafluorosulpholane-containing antidiabetic compounds
11/30/2011	EP2389368A1 Bridged and fused antidiabetic compounds
11/30/2011	EP2389366A1 Benzodiazepin-2-on derivatives
11/30/2011	EP2389365A1 Process for the preparation of rosuvastatin salts
11/30/2011	EP2389226A1 Bridged and fused heterocyclic antidiabetic compounds
11/30/2011	EP2389198A1 Site-specific monoconjugated insulinotropic glp-1 peptides
11/30/2011	EP2389190A2 Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
11/30/2011	EP2389183A1 Phosphate management with small molecules
11/30/2011	EP2389178A2 Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
11/30/2011	EP2389177A1 A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
11/30/2011	EP2389176A1 Novel metabolic disease therapy
11/30/2011	EP2389070A1 Disintegrable formulations of lanthanum carbonate
11/30/2011	EP2217583B1 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/30/2011	EP2010289B1 Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol
11/30/2011	EP1986566B1 Accelerating agent of calcium absorption
11/30/2011	EP1551810B1 Diaryl-substituted cyclic urea derivatives having an mch-modulatory effect

1 ... 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 ... 1298